Zhao Zeng

Prof. Zhao Zeng

The First Affiliated Hospital of Soochow University, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2021 in Autoimmunity
Verified
Journal Article
Open access
QLQiongyu Lu
Qiongyu Lu
PCPing Cai
Ping Cai
YYYan Yu
Yan Yu
ZLZiting Liu
Ziting Liu
GCGuona Chen
Guona Chen
ZZZhao Zeng
Zhao Zeng
Sema4D, a member of the immune semaphorin family, plays crucial roles in the immune regulation, bone resorption and nervous system. It is also involved in angiogenesis and tumour progression. However, systemic studies on the correlation between Sema4D expression and the immune infiltration or clinical outcomes in tumours are still limited. Here, we analysed the landscape of Sema4D expression and its prognostic value in the cancer genome atlas pan-cancer as well as the correlation between Sema4D and immune cell infiltration by Tumour Immune Estimation Resource and Gene Expression Profiling interactive analysis online tools. Results showed that a higher Sema4D expression was significantly correlated with a favourable overall survival in diverse solid tumours including bladder cancer (Hazards Ratio (HR)=0.68, p = .0095), kidney renal clear cell carcinoma (HR = 0.61, p = .0016), melanoma (HR = 0.58, p = 6.6e-05) and thymoma (HR = 0.1, p = .011). Interestingly, Sema4D expression has positive correlation with various tumour infiltrating immune cells and immune cell biomarkers in these tumours. These results suggest that Sema4D could be a prospective biomarker for calculating hazard ratio of tumour patients and their tumour immune infiltration levels.

26 April 2022 in Hematology
Verified
Journal Article
Open access
XXXin Xiang
Xin Xiang
QLQiongyu Lu
Qiongyu Lu
XXXiaoyu Xu
Xiaoyu Xu
PCPing Cai
Ping Cai
SCSuning Chen
Suning Chen
ZZZhao Zeng
Zhao Zeng
Cytogenetically normal acute myeloid leukemia (CN-AML) is a heterogeneous disease with variable clinical outcomes. The identification of potential biomarkers to better classify the patients with un...

7 February 2024 in British Journal of Haematology
Verified
Journal Article
Closed access
TZTingting Zhang
Tingting Zhang
YZYuqi Zhang
Yuqi Zhang
MZMeijia Zhou
Meijia Zhou
ZZZhibo Zhang
Zhibo Zhang
XBXiebing Bao
Xiebing Bao
SCSuning Chen
Suning Chen

30 November 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
PKPeng Ke
Peng Ke
JXJundan Xie
Jundan Xie
TXTing Xu
Ting Xu
MCMeiyu Chen
Meiyu Chen
YGYusha Guo
Yusha Guo
XBXiebing Bao
Xiebing Bao
Background: Satisfactory responses can be obtained for acute myeloid leukemia (AML) treated by Venetoclax (VEN)-based therapy. However, there are still quite a few AML patients (AMLs) resistant to VEN, and it is critical to understand whether VEN-resistance is regulated by senescence.Methods: Here, we established and validated a signature for predicting AML prognosis based on VEN resistance-related senescence genes (VRSGs). In this study, 51 senescence genes were identified with VEN-resistance in AML. Using LASSO algorithms and multiple AML cohorts, a VEN-resistance senescence prognostic model (VRSP-M) was developed and validated based on 6-senescence genes.Results: According to the median score of the signature, AMLs were classified into two subtypes. A worse prognosis and more adverse features occurred in the high-risk subtype, including older patients, non-de novo AML, poor cytogenetics, adverse risk of European LeukemiaNet (ELN) 2017 recommendation, and TP53 mutation. Patients in the high-risk subtype were mainly involved in monocyte differentiation, senescence, NADPH oxidases, and PD1 signaling pathway. The model’s risk score was significantly associated with VEN-resistance, immune features, and immunotherapy response in AML. In vitro, the IC50 values of ABT-199 (VEN) rose progressively with increasing expression of G6PD and BAG3 in AML cell lines.Conclusions: The 6-senescence genes prognostic model has significant meaning for the prediction of VEN-resistance, guiding personalized molecularly targeted therapies, and improving AML prognosis.

5 February 2024 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
GXGuo‐Fa Xu
Guo‐Fa Xu
ZZZhao Zeng
Zhao Zeng
ZZZhi‐Bo Zhang
Zhi‐Bo Zhang
XZXiao‐Mei Zhang
Xiao‐Mei Zhang
MWMan Wang
Man Wang
SCSu‐Ning Chen
Su‐Ning Chen
Patients with Philadelphia chromosome‐like acute lymphoblastic leukaemia (Ph‐like ALL) often face a grim prognosis, with PDGFRB gene fusions being commonly detected in this subgroup. Our study has unveiled a newfound fusion gene, TERF2::PDGFRB, and we have found that patients carrying this fusion gene exhibit sensitivity to dasatinib. Ba/F3 cells harbouring the TERF2::PDGFRB fusion display IL‐3‐independent cell proliferation through activation of the p‐PDGFRB and p‐STAT5 signalling pathways. These cells exhibit reduced apoptosis and demonstrate sensitivity to imatinib in vitro. When transfused into mice, Ba/F3 cells with the TERF2::PDGFRB fusion gene induce tumorigenesis and a shortened lifespan in cell‐derived graft models, but this outcome can be improved with imatinib treatment. In summary, we have identified the novel TERF2::PDGFRB fusion gene, which exhibits oncogenic potential both in vitro and in vivo, making it a potential therapeutic target for tyrosine kinase inhibitors (TKIs).

7 November 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
LGLijuan Gao
Lijuan Gao
QLQiongyu Lu
Qiongyu Lu
HLHao Li
Hao Li
CRChanggen Ruan
Changgen Ruan
ZZZhao Zeng
Zhao Zeng
SCSuning Chen
Suning Chen
Background: Extrachromosomal circular DNA (eccDNA) plays critical roles in cancer, yet its landscape in acute myeloid leukemia (AML) remains unexplored. Methods: We used CIRCLE-seq and RNA-seq to characterize eccDNA in 12 AML patients and 4 healthy controls. Results: AML cells showed significantly increased eccDNA counts and gene involvement versus healthy controls, with distinct size peaks at 202 and 368 bp. eccDNAs localized non-randomly to chromosomes 1, 2, and 10–19, enriching near transcription start sites and regulatory regions. Functional analysis revealed activation of oncogenic pathways (e.g., MAPK, ErbB signaling) in AML-associated eccDNA. Integrative analysis identified 570 genes upregulated at both the eccDNA and mRNA levels, including myeloid leukemia-related genes (e.g., FLT3 , RUNX1 , and CD33 ) and oncogenes. Prognostic analysis showed that high expression of these genes correlated with poor outcomes in AML. Conclusions: This study unveils the eccDNA landscape in AML by direct CIRCLE-seq, linking its accumulation to transcriptional dysregulation and leukemogenesis, and highlights eccDNA as a potential biomarker and therapeutic target.